Target intelligence / Profile preview

Putative non-classical estrogen-binding site

Molecular classification
Receptor, G protein-coupled receptor (for GPER1), Membrane receptor, Other (covers orphan and uncharacterized estrogen-binding proteins)
01

Overview

The "putative non-classical estrogen-binding site" refers to various molecular sites, principally located in the plasma membrane, that bind estrogen and mediate signaling independent of classical nuclear estrogen receptors. Notably, this includes G protein-coupled estrogen receptor 1 (GPER1), ER-X, and membrane forms of ERα/ERβ. These sites facilitate rapid, non-genomic signaling events, including modulation of ion channels and second messengers (such as cAMP), leading to transcriptional changes distinct from ERE-mediated gene activation. These mechanisms are implicated in neuroprotection, reproductive tissue development, and diseases including cancer and neurodegeneration. Importantly, the term lacks specificity and is used broadly to encompass a heterogeneous group of proteins and binding sites, of which GPER1 is the best-characterized[2][4][6].

Other names
Non-classical estrogen receptorMembrane estrogen-binding siteG protein-coupled estrogen receptor 1 (GPER1, formerly GPR30)ER-XMembrane ERα/ERβ isoforms
02

Mechanism of action

Rapid activation of intracellular second messenger pathways (cAMP, PI3K/Akt, MAPK); Ion channel modulation; Activation of transcription factors not dependent on estrogen response elements (e.g., CREB, AP-1); Membrane-initiated steroid signaling

03

Biological functions

Signal transductionRapid intracellular signalingRegulation of gene transcription (via ERE-independent mechanisms)NeuroprotectionModulation of endocrine feedbackCell survivalCell proliferation
04

Disease associations

Cancer (notably breast, ovarian)Neurodegenerative diseaseEndometriosis, reproductive disordersCardiovascular disease (suggested but not fully characterized)Other (potential roles in metabolic and autoimmune disease are under investigation)
05

Safety considerations

Off-target activity due to receptor promiscuityUnclear tissue specificityComplexity in distinguishing effects from classical and non-classical pathwaysPotential side effects relevant to rapid signaling modulation (e.g., cardiovascular, reproductive changes)
06

Interacting drugs

Estradiol (E2)

5 more in the full profile.

07

Biomarkers

GPER1 mRNA or protein level (in cancer, reproductive tissues)Downstream signaling molecules (e.g., phosphorylation of CREB, changes in cAMP levels)Changes in apoptosis or cell proliferation indices post-agonist exposure

Beyond the preview

Go deeper on Putative non-classical estrogen-binding site.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Putative non-classical estrogen-binding site.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call